nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0843	0.12	CbGbCtD
Lapatinib—CYP2C19—Prednisone—psoriatic arthritis	0.0633	0.0899	CbGbCtD
Lapatinib—ABCB1—Betamethasone—psoriatic arthritis	0.0548	0.0778	CbGbCtD
Lapatinib—ABCB1—Prednisolone—psoriatic arthritis	0.0541	0.0768	CbGbCtD
Lapatinib—ABCB1—Prednisone—psoriatic arthritis	0.0511	0.0725	CbGbCtD
Lapatinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0505	0.0717	CbGbCtD
Lapatinib—CYP3A5—Dexamethasone—psoriatic arthritis	0.049	0.0695	CbGbCtD
Lapatinib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0471	0.0669	CbGbCtD
Lapatinib—CYP2C19—Dexamethasone—psoriatic arthritis	0.0395	0.0561	CbGbCtD
Lapatinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0383	0.0543	CbGbCtD
Lapatinib—CYP3A4—Betamethasone—psoriatic arthritis	0.0328	0.0466	CbGbCtD
Lapatinib—CYP3A4—Prednisolone—psoriatic arthritis	0.0324	0.046	CbGbCtD
Lapatinib—ABCB1—Dexamethasone—psoriatic arthritis	0.0319	0.0453	CbGbCtD
Lapatinib—CYP3A4—Prednisone—psoriatic arthritis	0.0306	0.0434	CbGbCtD
Lapatinib—ABCB1—Methotrexate—psoriatic arthritis	0.0256	0.0364	CbGbCtD
Lapatinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.0191	0.0271	CbGbCtD
Lapatinib—TAP1—Antigen Presentation: Folding, assembly and peptide loading of class I MHC—HLA-C—psoriatic arthritis	0.0163	0.143	CbGpPWpGaD
Lapatinib—TAP1—Antigen Presentation: Folding, assembly and peptide loading of class I MHC—HLA-B—psoriatic arthritis	0.00962	0.0844	CbGpPWpGaD
Lapatinib—TAP1—ER-Phagosome pathway—HLA-C—psoriatic arthritis	0.00752	0.0659	CbGpPWpGaD
Lapatinib—Interstitial lung disease—Auranofin—psoriatic arthritis	0.00744	0.0443	CcSEcCtD
Lapatinib—TAP1—Type II interferon signaling (IFNG)—HLA-B—psoriatic arthritis	0.00681	0.0597	CbGpPWpGaD
Lapatinib—TAP1—Antigen processing-Cross presentation—HLA-C—psoriatic arthritis	0.00621	0.0544	CbGpPWpGaD
Lapatinib—Paronychia—Methotrexate—psoriatic arthritis	0.00588	0.035	CcSEcCtD
Lapatinib—TAP1—Type II interferon signaling (IFNG)—NOS2—psoriatic arthritis	0.00549	0.0481	CbGpPWpGaD
Lapatinib—Dermatitis acneiform—Triamcinolone—psoriatic arthritis	0.00452	0.0269	CcSEcCtD
Lapatinib—Dermatitis acneiform—Methylprednisolone—psoriatic arthritis	0.00451	0.0269	CcSEcCtD
Lapatinib—TAP1—ER-Phagosome pathway—HLA-B—psoriatic arthritis	0.00445	0.039	CbGpPWpGaD
Lapatinib—Dermatitis acneiform—Betamethasone—psoriatic arthritis	0.0041	0.0244	CcSEcCtD
Lapatinib—Dermatitis acneiform—Dexamethasone—psoriatic arthritis	0.0041	0.0244	CcSEcCtD
Lapatinib—ERBB4—EV release from cardiac cells and their functional effects—TNF—psoriatic arthritis	0.00382	0.0335	CbGpPWpGaD
Lapatinib—TAP1—Antigen processing-Cross presentation—HLA-B—psoriatic arthritis	0.00367	0.0322	CbGpPWpGaD
Lapatinib—Dermatitis acneiform—Prednisone—psoriatic arthritis	0.00357	0.0213	CcSEcCtD
Lapatinib—Neutropenia—Auranofin—psoriatic arthritis	0.00309	0.0184	CcSEcCtD
Lapatinib—Neuropathy peripheral—Auranofin—psoriatic arthritis	0.00289	0.0172	CcSEcCtD
Lapatinib—Stomatitis—Auranofin—psoriatic arthritis	0.00287	0.0171	CcSEcCtD
Lapatinib—ERBB2—Leptin signaling pathway—REL—psoriatic arthritis	0.00267	0.0234	CbGpPWpGaD
Lapatinib—TAP1—Class I MHC mediated antigen processing & presentation—HLA-C—psoriatic arthritis	0.00248	0.0217	CbGpPWpGaD
Lapatinib—Alopecia—Auranofin—psoriatic arthritis	0.00234	0.0139	CcSEcCtD
Lapatinib—Anaemia—Auranofin—psoriatic arthritis	0.00213	0.0127	CcSEcCtD
Lapatinib—Leukopenia—Auranofin—psoriatic arthritis	0.00206	0.0123	CcSEcCtD
Lapatinib—Mucosal inflammation—Methotrexate—psoriatic arthritis	0.00184	0.011	CcSEcCtD
Lapatinib—Anorexia—Auranofin—psoriatic arthritis	0.00179	0.0107	CcSEcCtD
Lapatinib—Dyspepsia—Auranofin—psoriatic arthritis	0.00165	0.00985	CcSEcCtD
Lapatinib—Decreased appetite—Auranofin—psoriatic arthritis	0.00163	0.00973	CcSEcCtD
Lapatinib—Constipation—Auranofin—psoriatic arthritis	0.00161	0.00957	CcSEcCtD
Lapatinib—Nail disorder—Methotrexate—psoriatic arthritis	0.00157	0.00937	CcSEcCtD
Lapatinib—Gastrointestinal pain—Auranofin—psoriatic arthritis	0.00154	0.00915	CcSEcCtD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00149	0.0131	CbGpPWpGaD
Lapatinib—Abdominal pain—Auranofin—psoriatic arthritis	0.00149	0.00885	CcSEcCtD
Lapatinib—TAP1—Class I MHC mediated antigen processing & presentation—HLA-B—psoriatic arthritis	0.00147	0.0129	CbGpPWpGaD
Lapatinib—TAP1—Immune System—MEFV—psoriatic arthritis	0.00145	0.0128	CbGpPWpGaD
Lapatinib—Interstitial lung disease—Methotrexate—psoriatic arthritis	0.00144	0.00858	CcSEcCtD
Lapatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00141	0.0123	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00139	0.0122	CbGpPWpGaD
Lapatinib—PIK3C2B—Exemestane—Methylprednisolone—psoriatic arthritis	0.00136	0.0992	CbGdCrCtD
Lapatinib—TAP1—Adaptive Immune System—REL—psoriatic arthritis	0.00133	0.0117	CbGpPWpGaD
Lapatinib—Pruritus—Auranofin—psoriatic arthritis	0.00133	0.00792	CcSEcCtD
Lapatinib—Hepatotoxicity—Methotrexate—psoriatic arthritis	0.00132	0.00787	CcSEcCtD
Lapatinib—Diarrhoea—Auranofin—psoriatic arthritis	0.00129	0.00766	CcSEcCtD
Lapatinib—ERBB2—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.00128	0.0112	CbGpPWpGaD
Lapatinib—ERBB2—B Cell Activation—REL—psoriatic arthritis	0.00124	0.0109	CbGpPWpGaD
Lapatinib—PIK3C2B—Exemestane—Prednisone—psoriatic arthritis	0.00124	0.0905	CbGdCrCtD
Lapatinib—ERBB2—DAP12 interactions—HLA-C—psoriatic arthritis	0.00124	0.0108	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.00123	0.0108	CbGpPWpGaD
Lapatinib—ERBB4—B Cell Activation—REL—psoriatic arthritis	0.00122	0.0107	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 interactions—HLA-C—psoriatic arthritis	0.00122	0.0107	CbGpPWpGaD
Lapatinib—PIK3C2B—Exemestane—Prednisolone—psoriatic arthritis	0.00121	0.0884	CbGdCrCtD
Lapatinib—Vomiting—Auranofin—psoriatic arthritis	0.0012	0.00712	CcSEcCtD
Lapatinib—Rash—Auranofin—psoriatic arthritis	0.00119	0.00706	CcSEcCtD
Lapatinib—Dermatitis—Auranofin—psoriatic arthritis	0.00118	0.00705	CcSEcCtD
Lapatinib—Cardiac failure—Methylprednisolone—psoriatic arthritis	0.00115	0.00683	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Methotrexate—psoriatic arthritis	0.00112	0.00668	CcSEcCtD
Lapatinib—ERBB2—Exemestane—Methylprednisolone—psoriatic arthritis	0.00112	0.0817	CbGdCrCtD
Lapatinib—Dry skin—Prednisolone—psoriatic arthritis	0.00112	0.00666	CcSEcCtD
Lapatinib—Nausea—Auranofin—psoriatic arthritis	0.00112	0.00665	CcSEcCtD
Lapatinib—Cardiac failure—Betamethasone—psoriatic arthritis	0.00104	0.00621	CcSEcCtD
Lapatinib—Cardiac failure—Dexamethasone—psoriatic arthritis	0.00104	0.00621	CcSEcCtD
Lapatinib—ERBB2—Exemestane—Prednisone—psoriatic arthritis	0.00102	0.0746	CbGdCrCtD
Lapatinib—ERBB2—Exemestane—Prednisolone—psoriatic arthritis	0.000999	0.0728	CbGdCrCtD
Lapatinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.000987	0.00588	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—MEFV—psoriatic arthritis	0.000939	0.00823	CbGpPWpGaD
Lapatinib—Dry skin—Betamethasone—psoriatic arthritis	0.000933	0.00555	CcSEcCtD
Lapatinib—Dry skin—Dexamethasone—psoriatic arthritis	0.000933	0.00555	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—MEFV—psoriatic arthritis	0.000924	0.0081	CbGpPWpGaD
Lapatinib—Neuropathy peripheral—Prednisolone—psoriatic arthritis	0.000921	0.00548	CcSEcCtD
Lapatinib—Cardiac failure—Prednisone—psoriatic arthritis	0.000908	0.00541	CcSEcCtD
Lapatinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.000862	0.00513	CcSEcCtD
Lapatinib—Infestation—Methylprednisolone—psoriatic arthritis	0.000862	0.00513	CcSEcCtD
Lapatinib—Neuropathy peripheral—Triamcinolone—psoriatic arthritis	0.000847	0.00504	CcSEcCtD
Lapatinib—Neuropathy peripheral—Methylprednisolone—psoriatic arthritis	0.000845	0.00503	CcSEcCtD
Lapatinib—Epistaxis—Triamcinolone—psoriatic arthritis	0.000815	0.00485	CcSEcCtD
Lapatinib—Dry skin—Prednisone—psoriatic arthritis	0.000812	0.00484	CcSEcCtD
Lapatinib—TAP1—Immune System—REL—psoriatic arthritis	0.000809	0.00709	CbGpPWpGaD
Lapatinib—Renal failure acute—Methotrexate—psoriatic arthritis	0.000802	0.00478	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.000782	0.00465	CcSEcCtD
Lapatinib—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.000769	0.00458	CcSEcCtD
Lapatinib—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.000769	0.00458	CcSEcCtD
Lapatinib—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.000761	0.00453	CcSEcCtD
Lapatinib—TAP1—Immune System—HLA-C—psoriatic arthritis	0.000745	0.00653	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 interactions—HLA-B—psoriatic arthritis	0.000731	0.00641	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000726	0.00636	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 interactions—HLA-B—psoriatic arthritis	0.00072	0.00631	CbGpPWpGaD
Lapatinib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000718	0.00428	CcSEcCtD
Lapatinib—Neutropenia—Prednisone—psoriatic arthritis	0.000716	0.00426	CcSEcCtD
Lapatinib—Angiopathy—Methylprednisolone—psoriatic arthritis	0.000702	0.00418	CcSEcCtD
Lapatinib—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.000699	0.00416	CcSEcCtD
Lapatinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000698	0.00415	CcSEcCtD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000681	0.00596	CbGpPWpGaD
Lapatinib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.000678	0.00404	CcSEcCtD
Lapatinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000674	0.00401	CcSEcCtD
Lapatinib—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.000669	0.00399	CcSEcCtD
Lapatinib—Back pain—Triamcinolone—psoriatic arthritis	0.000653	0.00389	CcSEcCtD
Lapatinib—Angiopathy—Betamethasone—psoriatic arthritis	0.000639	0.0038	CcSEcCtD
Lapatinib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000639	0.0038	CcSEcCtD
Lapatinib—EGFR—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000627	0.0055	CbGpPWpGaD
Lapatinib—Alopecia—Dexamethasone—psoriatic arthritis	0.000622	0.0037	CcSEcCtD
Lapatinib—Alopecia—Betamethasone—psoriatic arthritis	0.000622	0.0037	CcSEcCtD
Lapatinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.00062	0.00543	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000615	0.00539	CbGpPWpGaD
Lapatinib—ERBB2—Triamcinolone—Methylprednisolone—psoriatic arthritis	0.000611	0.0445	CbGdCrCtD
Lapatinib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000602	0.00359	CcSEcCtD
Lapatinib—EGFR—B Cell Activation—REL—psoriatic arthritis	0.000601	0.00527	CbGpPWpGaD
Lapatinib—ERBB2—Triamcinolone—Dexamethasone—psoriatic arthritis	0.000601	0.0438	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Betamethasone—psoriatic arthritis	0.000601	0.0438	CbGdCrCtD
Lapatinib—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000599	0.00357	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—psoriatic arthritis	0.000599	0.00356	CcSEcCtD
Lapatinib—EGFR—DAP12 interactions—HLA-C—psoriatic arthritis	0.000598	0.00524	CbGpPWpGaD
Lapatinib—Cough—Triamcinolone—psoriatic arthritis	0.000589	0.00351	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Methylprednisolone—psoriatic arthritis	0.00058	0.0423	CbGdCrCtD
Lapatinib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000575	0.00504	CbGpPWpGaD
Lapatinib—Myalgia—Triamcinolone—psoriatic arthritis	0.000575	0.00342	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—psoriatic arthritis	0.000574	0.00342	CcSEcCtD
Lapatinib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000574	0.00342	CcSEcCtD
Lapatinib—Myalgia—Methylprednisolone—psoriatic arthritis	0.000574	0.00342	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000572	0.00501	CbGpPWpGaD
Lapatinib—ERBB2—Desoximetasone—Dexamethasone—psoriatic arthritis	0.000571	0.0416	CbGdCrCtD
Lapatinib—ERBB2—Desoximetasone—Betamethasone—psoriatic arthritis	0.000571	0.0416	CbGdCrCtD
Lapatinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000571	0.0034	CcSEcCtD
Lapatinib—Infestation—Methotrexate—psoriatic arthritis	0.000571	0.0034	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00057	0.00339	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Triamcinolone—psoriatic arthritis	0.000558	0.0406	CbGdCrCtD
Lapatinib—ERBB2—Triamcinolone—Prednisone—psoriatic arthritis	0.000557	0.0406	CbGdCrCtD
Lapatinib—Stomatitis—Methotrexate—psoriatic arthritis	0.000556	0.00331	CcSEcCtD
Lapatinib—Angiopathy—Prednisone—psoriatic arthritis	0.000556	0.00331	CcSEcCtD
Lapatinib—Immune system disorder—Prednisone—psoriatic arthritis	0.000554	0.0033	CcSEcCtD
Lapatinib—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000551	0.00328	CcSEcCtD
Lapatinib—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00055	0.00327	CcSEcCtD
Lapatinib—TAP1—Immune System—NOD2—psoriatic arthritis	0.000548	0.0048	CbGpPWpGaD
Lapatinib—Infection—Triamcinolone—psoriatic arthritis	0.000548	0.00326	CcSEcCtD
Lapatinib—ERBB2—Immune System—MEFV—psoriatic arthritis	0.000547	0.00479	CbGpPWpGaD
Lapatinib—Infection—Methylprednisolone—psoriatic arthritis	0.000546	0.00325	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Prednisolone—psoriatic arthritis	0.000544	0.0396	CbGdCrCtD
Lapatinib—Insomnia—Prednisolone—psoriatic arthritis	0.000542	0.00323	CcSEcCtD
Lapatinib—Alopecia—Prednisone—psoriatic arthritis	0.000542	0.00323	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.00054	0.00321	CcSEcCtD
Lapatinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000539	0.00321	CcSEcCtD
Lapatinib—ERBB4—Immune System—MEFV—psoriatic arthritis	0.000538	0.00472	CbGpPWpGaD
Lapatinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000538	0.00321	CcSEcCtD
Lapatinib—Mental disorder—Prednisone—psoriatic arthritis	0.000537	0.0032	CcSEcCtD
Lapatinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000534	0.00318	CcSEcCtD
Lapatinib—Malnutrition—Prednisone—psoriatic arthritis	0.000534	0.00318	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisone—psoriatic arthritis	0.000529	0.0386	CbGdCrCtD
Lapatinib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.000526	0.00461	CbGpPWpGaD
Lapatinib—PIK3C2B—Danazol—Prednisone—psoriatic arthritis	0.000524	0.0382	CbGdCrCtD
Lapatinib—Myalgia—Dexamethasone—psoriatic arthritis	0.000522	0.00311	CcSEcCtD
Lapatinib—Myalgia—Betamethasone—psoriatic arthritis	0.000522	0.00311	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisolone—psoriatic arthritis	0.000517	0.0376	CbGdCrCtD
Lapatinib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000502	0.00299	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—REL—psoriatic arthritis	0.000501	0.00439	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000501	0.00298	CcSEcCtD
Lapatinib—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.0005	0.00298	CcSEcCtD
Lapatinib—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.0005	0.00298	CcSEcCtD
Lapatinib—Insomnia—Triamcinolone—psoriatic arthritis	0.000499	0.00297	CcSEcCtD
Lapatinib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000497	0.00296	CcSEcCtD
Lapatinib—Infection—Dexamethasone—psoriatic arthritis	0.000497	0.00296	CcSEcCtD
Lapatinib—Infection—Betamethasone—psoriatic arthritis	0.000497	0.00296	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—REL—psoriatic arthritis	0.000494	0.00433	CbGpPWpGaD
Lapatinib—Anaemia—Prednisone—psoriatic arthritis	0.000493	0.00294	CcSEcCtD
Lapatinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000491	0.00293	CcSEcCtD
Lapatinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00049	0.00292	CcSEcCtD
Lapatinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00049	0.00292	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.000489	0.00429	CbGpPWpGaD
Lapatinib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000485	0.00289	CcSEcCtD
Lapatinib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000484	0.00288	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—HLA-C—psoriatic arthritis	0.00048	0.00421	CbGpPWpGaD
Lapatinib—Anorexia—Dexamethasone—psoriatic arthritis	0.000477	0.00284	CcSEcCtD
Lapatinib—Anorexia—Betamethasone—psoriatic arthritis	0.000477	0.00284	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000475	0.00283	CcSEcCtD
Lapatinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000475	0.00283	CcSEcCtD
Lapatinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000474	0.00282	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—HLA-C—psoriatic arthritis	0.000473	0.00415	CbGpPWpGaD
Lapatinib—Angiopathy—Methotrexate—psoriatic arthritis	0.000465	0.00277	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—psoriatic arthritis	0.000463	0.00276	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000462	0.00275	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000461	0.00404	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000456	0.00271	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000456	0.00271	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000454	0.00398	CbGpPWpGaD
Lapatinib—Arthralgia—Prednisone—psoriatic arthritis	0.000454	0.00271	CcSEcCtD
Lapatinib—Myalgia—Prednisone—psoriatic arthritis	0.000454	0.00271	CcSEcCtD
Lapatinib—EGFR—Innate Immune System—MEFV—psoriatic arthritis	0.000454	0.00398	CbGpPWpGaD
Lapatinib—Alopecia—Methotrexate—psoriatic arthritis	0.000453	0.0027	CcSEcCtD
Lapatinib—Insomnia—Dexamethasone—psoriatic arthritis	0.000452	0.00269	CcSEcCtD
Lapatinib—Insomnia—Betamethasone—psoriatic arthritis	0.000452	0.00269	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000451	0.00269	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00045	0.00268	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—psoriatic arthritis	0.000449	0.00267	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000446	0.00266	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000442	0.00263	CcSEcCtD
Lapatinib—TAP1—Immune System—HLA-B—psoriatic arthritis	0.00044	0.00386	CbGpPWpGaD
Lapatinib—Dyspepsia—Betamethasone—psoriatic arthritis	0.00044	0.00262	CcSEcCtD
Lapatinib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00044	0.00262	CcSEcCtD
Lapatinib—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000436	0.00259	CcSEcCtD
Lapatinib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000435	0.00259	CcSEcCtD
Lapatinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000435	0.00259	CcSEcCtD
Lapatinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000435	0.00259	CcSEcCtD
Lapatinib—Infection—Prednisone—psoriatic arthritis	0.000433	0.00258	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000432	0.00257	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000432	0.00257	CcSEcCtD
Lapatinib—Back pain—Methotrexate—psoriatic arthritis	0.000431	0.00257	CcSEcCtD
Lapatinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000431	0.00257	CcSEcCtD
Lapatinib—Fatigue—Betamethasone—psoriatic arthritis	0.000431	0.00257	CcSEcCtD
Lapatinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000427	0.00254	CcSEcCtD
Lapatinib—Skin disorder—Prednisone—psoriatic arthritis	0.000423	0.00252	CcSEcCtD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000416	0.00364	CbGpPWpGaD
Lapatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000416	0.00364	CbGpPWpGaD
Lapatinib—Anorexia—Prednisone—psoriatic arthritis	0.000415	0.00247	CcSEcCtD
Lapatinib—Anaemia—Methotrexate—psoriatic arthritis	0.000412	0.00245	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000409	0.00243	CcSEcCtD
Lapatinib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000409	0.00243	CcSEcCtD
Lapatinib—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000406	0.00242	CcSEcCtD
Lapatinib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000405	0.00241	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—psoriatic arthritis	0.000399	0.00238	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000397	0.00236	CcSEcCtD
Lapatinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000395	0.00235	CcSEcCtD
Lapatinib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000395	0.00235	CcSEcCtD
Lapatinib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000395	0.00235	CcSEcCtD
Lapatinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000395	0.00235	CcSEcCtD
Lapatinib—EGFR—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000394	0.00345	CbGpPWpGaD
Lapatinib—Insomnia—Prednisone—psoriatic arthritis	0.000394	0.00235	CcSEcCtD
Lapatinib—Pruritus—Triamcinolone—psoriatic arthritis	0.00039	0.00232	CcSEcCtD
Lapatinib—TAP1—Immune System—CRP—psoriatic arthritis	0.000389	0.00341	CbGpPWpGaD
Lapatinib—Cough—Methotrexate—psoriatic arthritis	0.000389	0.00232	CcSEcCtD
Lapatinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000389	0.00232	CcSEcCtD
Lapatinib—Dyspepsia—Prednisone—psoriatic arthritis	0.000383	0.00228	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—psoriatic arthritis	0.00038	0.00226	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—psoriatic arthritis	0.00038	0.00226	CcSEcCtD
Lapatinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000379	0.00225	CcSEcCtD
Lapatinib—Rash—Prednisolone—psoriatic arthritis	0.000378	0.00225	CcSEcCtD
Lapatinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000378	0.00225	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000377	0.00225	CcSEcCtD
Lapatinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000376	0.00224	CcSEcCtD
Lapatinib—Fatigue—Prednisone—psoriatic arthritis	0.000375	0.00224	CcSEcCtD
Lapatinib—Headache—Prednisolone—psoriatic arthritis	0.000375	0.00224	CcSEcCtD
Lapatinib—TAP1—Immune System—HLA-DRB1—psoriatic arthritis	0.000373	0.00327	CbGpPWpGaD
Lapatinib—Constipation—Prednisone—psoriatic arthritis	0.000372	0.00222	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000364	0.00217	CcSEcCtD
Lapatinib—Infection—Methotrexate—psoriatic arthritis	0.000362	0.00215	CcSEcCtD
Lapatinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000359	0.00214	CcSEcCtD
Lapatinib—Asthenia—Betamethasone—psoriatic arthritis	0.000359	0.00214	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000357	0.00213	CcSEcCtD
Lapatinib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000356	0.00212	CcSEcCtD
Lapatinib—Nausea—Prednisolone—psoriatic arthritis	0.000356	0.00212	CcSEcCtD
Lapatinib—Pruritus—Betamethasone—psoriatic arthritis	0.000354	0.00211	CcSEcCtD
Lapatinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000354	0.00211	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000354	0.00211	CcSEcCtD
Lapatinib—EGFR—DAP12 interactions—HLA-B—psoriatic arthritis	0.000354	0.0031	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—NOD2—psoriatic arthritis	0.000353	0.0031	CbGpPWpGaD
Lapatinib—Vomiting—Triamcinolone—psoriatic arthritis	0.00035	0.00209	CcSEcCtD
Lapatinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.00035	0.00208	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—NOD2—psoriatic arthritis	0.000348	0.00305	CbGpPWpGaD
Lapatinib—Rash—Triamcinolone—psoriatic arthritis	0.000348	0.00207	CcSEcCtD
Lapatinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000347	0.00207	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—psoriatic arthritis	0.000347	0.00207	CcSEcCtD
Lapatinib—Rash—Methylprednisolone—psoriatic arthritis	0.000347	0.00206	CcSEcCtD
Lapatinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000346	0.00206	CcSEcCtD
Lapatinib—Headache—Triamcinolone—psoriatic arthritis	0.000345	0.00206	CcSEcCtD
Lapatinib—Headache—Methylprednisolone—psoriatic arthritis	0.000345	0.00205	CcSEcCtD
Lapatinib—Abdominal pain—Prednisone—psoriatic arthritis	0.000344	0.00205	CcSEcCtD
Lapatinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000342	0.00204	CcSEcCtD
Lapatinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000342	0.00204	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.00034	0.00298	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000332	0.00197	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—psoriatic arthritis	0.000329	0.00196	CcSEcCtD
Lapatinib—Nausea—Triamcinolone—psoriatic arthritis	0.000327	0.00195	CcSEcCtD
Lapatinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000327	0.00194	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000325	0.00193	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisone—psoriatic arthritis	0.000321	0.00191	CcSEcCtD
Lapatinib—Dyspepsia—Methotrexate—psoriatic arthritis	0.00032	0.00191	CcSEcCtD
Lapatinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000318	0.00189	CcSEcCtD
Lapatinib—Vomiting—Betamethasone—psoriatic arthritis	0.000318	0.00189	CcSEcCtD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000317	0.00278	CbGpPWpGaD
Lapatinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000316	0.00188	CcSEcCtD
Lapatinib—Rash—Betamethasone—psoriatic arthritis	0.000315	0.00188	CcSEcCtD
Lapatinib—Rash—Dexamethasone—psoriatic arthritis	0.000315	0.00188	CcSEcCtD
Lapatinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000315	0.00188	CcSEcCtD
Lapatinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000315	0.00188	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000314	0.00187	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—psoriatic arthritis	0.000314	0.00187	CcSEcCtD
Lapatinib—Headache—Dexamethasone—psoriatic arthritis	0.000313	0.00187	CcSEcCtD
Lapatinib—Headache—Betamethasone—psoriatic arthritis	0.000313	0.00187	CcSEcCtD
Lapatinib—Asthenia—Prednisone—psoriatic arthritis	0.000312	0.00186	CcSEcCtD
Lapatinib—Pruritus—Prednisone—psoriatic arthritis	0.000308	0.00183	CcSEcCtD
Lapatinib—ERBB2—Immune System—REL—psoriatic arthritis	0.000304	0.00267	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—REL—psoriatic arthritis	0.0003	0.00263	CbGpPWpGaD
Lapatinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000298	0.00177	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000298	0.00177	CcSEcCtD
Lapatinib—Nausea—Betamethasone—psoriatic arthritis	0.000297	0.00177	CcSEcCtD
Lapatinib—Nausea—Dexamethasone—psoriatic arthritis	0.000297	0.00177	CcSEcCtD
Lapatinib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000288	0.00252	CbGpPWpGaD
Lapatinib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000288	0.00171	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—HLA-B—psoriatic arthritis	0.000284	0.00249	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—HLA-B—psoriatic arthritis	0.00028	0.00245	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-C—psoriatic arthritis	0.00028	0.00245	CbGpPWpGaD
Lapatinib—Vomiting—Prednisone—psoriatic arthritis	0.000277	0.00165	CcSEcCtD
Lapatinib—ERBB4—Immune System—HLA-C—psoriatic arthritis	0.000276	0.00242	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000275	0.00241	CbGpPWpGaD
Lapatinib—Rash—Prednisone—psoriatic arthritis	0.000275	0.00164	CcSEcCtD
Lapatinib—Dermatitis—Prednisone—psoriatic arthritis	0.000274	0.00163	CcSEcCtD
Lapatinib—Headache—Prednisone—psoriatic arthritis	0.000273	0.00162	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000273	0.00239	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000269	0.00236	CbGpPWpGaD
Lapatinib—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000268	0.0016	CcSEcCtD
Lapatinib—EGFR—Immune System—MEFV—psoriatic arthritis	0.000264	0.00232	CbGpPWpGaD
Lapatinib—Asthenia—Methotrexate—psoriatic arthritis	0.000261	0.00155	CcSEcCtD
Lapatinib—Nausea—Prednisone—psoriatic arthritis	0.000259	0.00154	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—psoriatic arthritis	0.000258	0.00153	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—CRP—psoriatic arthritis	0.000251	0.0022	CbGpPWpGaD
Lapatinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000249	0.00148	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—CRP—psoriatic arthritis	0.000247	0.00217	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—REL—psoriatic arthritis	0.000242	0.00212	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HLA-C—psoriatic arthritis	0.000232	0.00204	CbGpPWpGaD
Lapatinib—Vomiting—Methotrexate—psoriatic arthritis	0.000231	0.00138	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000231	0.00202	CbGpPWpGaD
Lapatinib—Rash—Methotrexate—psoriatic arthritis	0.000229	0.00137	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000229	0.00137	CcSEcCtD
Lapatinib—Headache—Methotrexate—psoriatic arthritis	0.000228	0.00136	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000227	0.00199	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000223	0.00195	CbGpPWpGaD
Lapatinib—Nausea—Methotrexate—psoriatic arthritis	0.000216	0.00129	CcSEcCtD
Lapatinib—ERBB2—Immune System—NOD2—psoriatic arthritis	0.000206	0.0018	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—NOD2—psoriatic arthritis	0.000203	0.00178	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TNF—psoriatic arthritis	0.000196	0.00171	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NOD2—psoriatic arthritis	0.000171	0.0015	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-B—psoriatic arthritis	0.000165	0.00145	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-B—psoriatic arthritis	0.000163	0.00143	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000147	0.00129	CbGpPWpGaD
Lapatinib—EGFR—Immune System—REL—psoriatic arthritis	0.000147	0.00129	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—CRP—psoriatic arthritis	0.000146	0.00128	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—CRP—psoriatic arthritis	0.000144	0.00126	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HLA-DRB1—psoriatic arthritis	0.00014	0.00123	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HLA-DRB1—psoriatic arthritis	0.000138	0.00121	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HLA-B—psoriatic arthritis	0.000137	0.0012	CbGpPWpGaD
Lapatinib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	0.000136	0.00119	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-C—psoriatic arthritis	0.000135	0.00119	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000133	0.00117	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000132	0.00116	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—TNF—psoriatic arthritis	0.000129	0.00113	CbGpPWpGaD
Lapatinib—ERBB2—Disease—NOS2—psoriatic arthritis	0.000123	0.00108	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—CRP—psoriatic arthritis	0.000121	0.00106	CbGpPWpGaD
Lapatinib—ERBB4—Disease—NOS2—psoriatic arthritis	0.000121	0.00106	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000112	0.000979	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NOD2—psoriatic arthritis	9.95e-05	0.000872	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-B—psoriatic arthritis	8e-05	0.000701	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CRP—psoriatic arthritis	7.07e-05	0.00062	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HLA-DRB1—psoriatic arthritis	6.77e-05	0.000594	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	6.72e-05	0.000589	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TNF—psoriatic arthritis	6.22e-05	0.000545	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOS2—psoriatic arthritis	5.95e-05	0.000522	CbGpPWpGaD
